New Era in Biologics Development: WuXi Biologics Unveils TrueSite TI™ Platform
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has unveiled TrueSite TI™, a next-generation CHO cell line platform built on targeted integration technology. Designed to transform biologics development, this innovation accelerates development timelines, enhances product…